Literature DB >> 17038352

Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides.

Emi Shoji-Hosaka1, Yukari Kobayashi, Masako Wakitani, Kazuhisa Uchida, Rinpei Niwa, Kazuyasu Nakamura, Kenya Shitara.   

Abstract

Fucose removal from complex-type oligosaccharide of human IgGs results in a major enhancement of Fc-dependent cellular cytotoxicity. The aim of this study was to determine the effect of fucose removal on the effector function of another class of clinically important molecules that can effect cellular cytotoxicity, Fc fusion proteins. The receptors chosen for study were TNF receptor II and LFA-3, both of which have therapeutic significance. The fucosylated versions of these fusion proteins were produced in unmodified CHO cells, whereas the nonfucosylated counterparts were produced in CHO cells with alpha-1,6-fucosyltransferase, an enzyme required for fucosylation, knocked-out. Whilst binding activity of TNFRII-Fc and LFA-3-Fc were unchanged by fucose-removal, nonfucosylated Fc fusion proteins exhibited significantly higher Fc receptor gammaIIIa-binding and increased Fc-mediated cytotoxicity on target cells compared to fucosylated counterparts. Notably, in case of TNFRII-Fc, only the nonfucosylated protein exhibited potent Fc dependent cytotoxicity to transmembrane TNF-alpha expressing cells. These results prove that enhancement of Fc dependent cellular cytotoxicity by fucose-removal is effective in not only whole IgG but also Fc fusion proteins, and thus widens the potential of Fc-fusion proteins as therapeutic candidates.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17038352     DOI: 10.1093/jb/mvj207

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  9 in total

1.  Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities.

Authors:  Shan Chung; Valerie Quarmby; Xiaoying Gao; Yong Ying; Linda Lin; Chae Reed; Chris Fong; Wendy Lau; Zhihua J Qiu; Amy Shen; Martin Vanderlaan; An Song
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

2.  Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor.

Authors:  Qing-Hui Zhou; Rachita Sumbria; Eric Ka-Wai Hui; Jeff Zhiqiang Lu; Ruben J Boado; William M Pardridge
Journal:  J Pharmacol Exp Ther       Date:  2011-08-10       Impact factor: 4.030

Review 3.  Production of therapeutic antibodies with controlled fucosylation.

Authors:  Naoko Yamane-Ohnuki; Mitsuo Satoh
Journal:  MAbs       Date:  2009-05-28       Impact factor: 5.857

4.  A method for high-throughput, sensitive analysis of IgG Fc and Fab glycosylation by capillary electrophoresis.

Authors:  Alison E Mahan; Jacquelynne Tedesco; Kendall Dionne; Kavitha Baruah; Hao D Cheng; Philip L De Jager; Dan H Barouch; Todd Suscovich; Margaret Ackerman; Max Crispin; Galit Alter
Journal:  J Immunol Methods       Date:  2014-12-15       Impact factor: 2.303

5.  Profiling of N-Linked Oligosaccharides of a Glycoprotein by UPLC-FLR-ESI-MS After Derivatization with Fluorescent Anthranilamide.

Authors:  Claire I Butré; Eric Largy; Arnaud Delobel
Journal:  Methods Mol Biol       Date:  2021

Review 6.  A Historical Review of Brain Drug Delivery.

Authors:  William M Pardridge
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

7.  Engineering of Humanized Antibodies Against Human Interleukin 5 Receptor Alpha Subunit That Cause Potent Antibody-Dependent Cell-Mediated Cytotoxicity.

Authors:  Jung-Eun Kim; Dong-Hyun Lee; Keunok Jung; Eun-Ji Kim; Youngwoo Choi; Hae-Sim Park; Yong-Sung Kim
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

8.  Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC.

Authors:  Akito Natsume; Rinpei Niwa; Mitsuo Satoh
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

Review 9.  Fc-fusion proteins: new developments and future perspectives.

Authors:  Daniel M Czajkowsky; Jun Hu; Zhifeng Shao; Richard J Pleass
Journal:  EMBO Mol Med       Date:  2012-07-26       Impact factor: 12.137

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.